Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

Ozempic is under clinical development by Novo Nordisk and currently in Phase III for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

In recent developments, health officials in Europe have launched an investigation into the popular weight loss drug Ozempic, ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

Oh, oh, oh, with Khloe Kardashian now chiming in, it seems everyone in Hollywood—including Jessica Simpson, Sophie Turner, ...

Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...